MedPath

Efficacy and Safety of Egalet-002 in Patients With Moderate-to-Severe Chronic Low Back Pain

Phase 3
Completed
Conditions
Moderate-to-severe Chronic Low Back Pain
Interventions
Drug: Placebo of oxycodone extended-release
Registration Number
NCT02716857
Lead Sponsor
Egalet Ltd
Brief Summary

The purpose of this study is to determine the analgesic efficacy of Egalet-002 twice daily (BID) in patients with moderate-to-severe chronic low back pain

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
549
Inclusion Criteria
  • Is an English-speaking man or woman between 18 and 75 years of age who has given written informed consent.
  • Has a clinical diagnosis of moderate-to-severe low back pain (Quebec Task Force Class 1 to 3) for ≥6 months.
  • Is opioid naïve (ie, taking <20 mg oxycodone/day or opioid equivalent) or is opioid experienced (ie, taking a dose between 20 and 240 mg [inclusive] oxycodone/day or opioid equivalent) for management of moderate-to-severe CLBP at least 14 days prior to screening and will, in the opinion of the investigator, continue to require opioid therapy (between 20 and 240 mg oxycodone/day, inclusive) for management of moderate-to-severe CLBP for the duration of the study.
  • Has stable health, as determined by the investigator,
  • If female, the patient is currently not pregnant, not breast-feeding, nor attempting to become pregnant (for 30 days before screening and throughout the duration of the study), or is of non-childbearing potential
Exclusion Criteria
  • Has cancer-related pain.
  • Has a history of receiving >240 mg oxycodone (or equivalent) daily within 30 days before screening.
  • Has a lumbar spinal infusion pump in use or used within 6 months before screening.
  • Has clinically unstable cardiac disease (including atrial fibrillation, symptomatic bradycardia, unstable congestive heart failure, or active myocardial ischemia)
  • Has positive urine drug toxicity screen for illegal or non-prescribed drugs
  • Has current (or history of within the last 5 years prior to screening) drug dependence or substance abuse disorder according to Diagnostic and Statistical Manual of Mental Disorders, 5th Edition, Text Revision criteria (excluding nicotine).
  • Has positive result for cannabinoids (even if legally prescribed).
  • Has a history of attempted suicide.

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Oxycodone extended-releaseOxycodone extended-releaseEgalet ADER oxycodone tablet
Placebo of Oxycodone extended-releasePlacebo of oxycodone extended-releaseEgalet ADER oxycodone placebo tablet
Primary Outcome Measures
NameTimeMethod
Measure of Average Pain Intensity past 24 hours, as measured by a 0-10 NPRS using eDiary collection daily at bedtime.16 weeks
Secondary Outcome Measures
NameTimeMethod
Efficacy: daily (past 24 hours) worst pain intensity score (WPI)16 Weeks
Safety: Incidence of TEAEs, including those leading to treatment withdrawal, and/or abnormal physical examination findings, vital signs measurements, ECGs, and clinical laboratory test results, related to treatment16 weeks

Trial Locations

Locations (74)

Site 245

🇺🇸

Boise, Idaho, United States

Site 251

🇺🇸

Spartanburg, South Carolina, United States

Site 226

🇺🇸

Boston, Massachusetts, United States

Site 277

🇺🇸

Overland Park, Kansas, United States

Site 207

🇺🇸

Birmingham, Alabama, United States

Site 265

🇺🇸

Omaha, Nebraska, United States

Site 269

🇺🇸

Inverness, Florida, United States

Site 282

🇺🇸

Tucson, Arizona, United States

Site 217

🇺🇸

Anaheim, California, United States

Site 209

🇺🇸

Franklin, Ohio, United States

Site 259

🇺🇸

Kettering, Ohio, United States

Site 239

🇺🇸

Oklahoma City, Oklahoma, United States

Site 247

🇺🇸

Greenville, South Carolina, United States

Site 219

🇺🇸

Richardson, Texas, United States

Site 240

🇺🇸

Toledo, Ohio, United States

Site 267

🇺🇸

Somerset, New Jersey, United States

Site 205

🇺🇸

Charleston, South Carolina, United States

Site 241

🇺🇸

Everett, Washington, United States

Site 218

🇺🇸

Austin, Texas, United States

Site 257

🇺🇸

Spokane, Washington, United States

Site 256

🇺🇸

Jenkintown, Pennsylvania, United States

Site 264

🇺🇸

Sarasota, Florida, United States

Site 260

🇺🇸

Phoenix, Arizona, United States

Site 268

🇺🇸

Phoenix, Arizona, United States

Site 280

🇺🇸

Anaheim, California, United States

Site 235

🇺🇸

Laguna Hills, California, United States

Site 215

🇺🇸

Long Beach, California, United States

Site 238

🇺🇸

Los Gatos, California, United States

Site 231

🇺🇸

San Diego, California, United States

Site 237

🇺🇸

San Diego, California, United States

Site 225

🇺🇸

Sacramento, California, United States

Site 221

🇺🇸

Wildomar, California, United States

Site 228

🇺🇸

Bradenton, Florida, United States

Site 248

🇺🇸

Boulder, Colorado, United States

Site 214

🇺🇸

Clearwater, Florida, United States

Site 270

🇺🇸

Gainesville, Florida, United States

Site 227

🇺🇸

Jupiter, Florida, United States

Site 229

🇺🇸

Miami Beach, Florida, United States

SIte 204

🇺🇸

Lake Worth, Florida, United States

Site 223

🇺🇸

Atlanta, Georgia, United States

Site 255

🇺🇸

Chicago, Illinois, United States

Site 222

🇺🇸

Evansville, Indiana, United States

SIte 236

🇺🇸

West Des Moines, Iowa, United States

Site 206

🇺🇸

New Orleans, Louisiana, United States

Site 224

🇺🇸

Shreveport, Louisiana, United States

Site 249

🇺🇸

Pikesville, Maryland, United States

Site 254

🇺🇸

New Bedford, Massachusetts, United States

Site 210

🇺🇸

Bay City, Michigan, United States

Site 234

🇺🇸

Hazelwood, Missouri, United States

Site 261

🇺🇸

Kew Gardens, New York, United States

Site 243

🇺🇸

New York, New York, United States

Site 208

🇺🇸

Williamsville, New York, United States

Site 233

🇺🇸

Rochester, New York, United States

Site 203

🇺🇸

Charlotte, North Carolina, United States

Site 213

🇺🇸

Winston-Salem, North Carolina, United States

Site 276

🇺🇸

Columbus, Ohio, United States

Site 242

🇺🇸

Winston-Salem, North Carolina, United States

Site 263

🇺🇸

Hurst, Texas, United States

Site 202

🇺🇸

Mobile, Alabama, United States

Site 278

🇺🇸

Plantation, Florida, United States

Site 212

🇺🇸

Marietta, Georgia, United States

Site 253

🇺🇸

Phoenix, Arizona, United States

Site 258

🇺🇸

Lansdale, Pennsylvania, United States

Site 232

🇺🇸

Port Orange, Florida, United States

Site 201

🇺🇸

Oakland, California, United States

Site 275

🇺🇸

San Antonio, Texas, United States

Site 220

🇺🇸

La Mesa, California, United States

Site 271

🇺🇸

Winter Park, Florida, United States

Site 262

🇺🇸

Napa, California, United States

Site 266

🇺🇸

Princeton, New Jersey, United States

Site 252

🇺🇸

Albuquerque, New Mexico, United States

Site 244

🇺🇸

Jackson, Mississippi, United States

Site 279

🇺🇸

Duncansville, Pennsylvania, United States

Site 211

🇺🇸

Miami Beach, Florida, United States

© Copyright 2025. All Rights Reserved by MedPath